| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 01/22/2009 | US20090022724 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 01/22/2009 | US20090022723 Anti-il-tif antibodies and methods of using in inflammation |
| 01/22/2009 | US20090022722 Cytotoxicity mediation of cells evidencing surface expression of CD59 |
| 01/22/2009 | US20090022721 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| 01/22/2009 | US20090022720 Conjugate of an antibody against CD4 and antifusogenic peptides |
| 01/22/2009 | US20090022719 Preventive and/or therapeutic method for systemic lupus erythematosus comprising anti-IL-6 receptor antibody administration |
| 01/22/2009 | US20090022718 Methods of treating a blood pathology using anti-TNF antibodies and fragments thereof |
| 01/22/2009 | US20090022717 Antibodies that bind cxcr7 epitopes |
| 01/22/2009 | US20090022716 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 01/22/2009 | US20090022715 Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof |
| 01/22/2009 | US20090022714 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 01/22/2009 | US20090022713 Anti-pro87299 antibodies |
| 01/22/2009 | US20090022709 Control of sorbose utilization genes and uses thereof |
| 01/22/2009 | US20090022707 contacting target cells with a therapeutic quantity of a soluble antibody that specifically binds tumor necrosis factor-related apoptosis inducing ligand receptor(TRAIL) DR5, and contacting target cells with a therapeutic agent |
| 01/22/2009 | US20090022704 Method for the treatment of gout or pseudogout |
| 01/22/2009 | US20090022662 Cancerous disease modifying antibodies |
| 01/22/2009 | US20090022661 Cancerous disease modifying antibodies |
| 01/22/2009 | US20090022660 Monoclonal antibodies comprising cytotoxic agent capable of inducing antibody dependent cellular cytotoxicity directed towards tumorus tissues |
| 01/22/2009 | US20090022659 Antibodies to TNF alpha and use thereof |
| 01/22/2009 | US20090022658 Modified antibodies and methods of use |
| 01/22/2009 | DE112006003813T5 Wasserlösliche Konjugate zur elektrochemischen Detektion Water-soluble conjugates for electrochemical detection |
| 01/22/2009 | CA2696437A1 Production and use of epitope-tagged hepatitis c virus particle |
| 01/22/2009 | CA2694737A1 Single-domain antigen-binding proteins that bind mammalian igg |
| 01/22/2009 | CA2693863A1 Engineered anti-alpha v- integrin hybrid antibodies |
| 01/22/2009 | CA2693443A1 Variable tangential flow filtration |
| 01/22/2009 | CA2693255A1 Anti-cd79b antibodies and immunoconjugates and methods of use |
| 01/22/2009 | CA2693201A1 Antagonist antibodies of protease activated receptor-1 (par1) |
| 01/22/2009 | CA2693137A1 Engineered scfv against bovine herpes virus type i |
| 01/22/2009 | CA2692912A1 An anti-cancer cytotoxic monoclonal antibody |
| 01/22/2009 | CA2692826A1 An anti-cancer cytotoxic monoclonal antibody |
| 01/22/2009 | CA2692823A1 An anti-cancer cytotoxic monoclonal antibody |
| 01/22/2009 | CA2692819A1 Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| 01/22/2009 | CA2692693A1 Optimized dna and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins |
| 01/21/2009 | EP2017341A2 Apo-2 ligand |
| 01/21/2009 | EP2017286A2 Transporter genes |
| 01/21/2009 | EP2016954A1 Antibodies against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and metabolites thereof |
| 01/21/2009 | EP2016953A2 Vascular endothelial cell growth factor antagonists and uses thereof |
| 01/21/2009 | EP2016951A1 Polypeptides homologous to VEGF and BMP1 |
| 01/21/2009 | EP2016949A1 Novel use of g-protein-conjugated receptor and ligand thereof |
| 01/21/2009 | EP2016162A2 Humanized monoclonal antibodies to hepatocyte growth factor |
| 01/21/2009 | EP2016101A2 Binding polypeptides with optimized scaffolds |
| 01/21/2009 | EP2016100A2 Hcv coreceptor and methods of use thereof |
| 01/21/2009 | EP2016098A1 Antibody-targeted cytokines for therapy |
| 01/21/2009 | EP2015776A1 Glp-1 compound/glucagon antibody compositions |
| 01/21/2009 | EP2015775A1 Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody |
| 01/21/2009 | EP2015772A2 Agent for the treatment of malignant diseases |
| 01/21/2009 | EP2015771A1 Modulation of t helper cell-mediated immune responses |
| 01/21/2009 | EP1585770B1 Recognition molecules for the treatment and detection of tumours |
| 01/21/2009 | EP1432443B1 Angiotensin peptide-carrier conjugates and uses thereof |
| 01/21/2009 | EP1353691B1 Molecular antigen array presenting amyloid beta |
| 01/21/2009 | EP1335973B1 human adenylate cyclase |
| 01/21/2009 | EP1234880B1 Novel protein tab2 |
| 01/21/2009 | EP1019438B1 Apoptosis-related compounds and their use |
| 01/21/2009 | EP1007546B1 Molecular mimetics of meningococcal b epitopes |
| 01/21/2009 | EP0975760B1 Motilin homologs |
| 01/21/2009 | CN101351478A Uses of anti-CD40 antibodies |
| 01/21/2009 | CN101351477A Anti-CD19 antibodies with reduced immunogenicity |
| 01/21/2009 | CN101351476A Antibodies with glycosylated in the variable region |
| 01/21/2009 | CN101351221A Outer coat protein PA5158 of pseudomonas aeruginosa |
| 01/21/2009 | CN101348777A Influenza A virus ELISA nucleoprotein capture antigen diagnose reagent kit and special monoclonal antibody therefor |
| 01/21/2009 | CN101348526A Anti-interleukin-8 antibody |
| 01/21/2009 | CN101348525A Anti-schistosomiasis monoclonal antibody NP11-4 single-chain antibody, preparation and use thereof |
| 01/21/2009 | CN100453645C Antibodies against insulin-like growth factor i receptor and uses thereof |
| 01/21/2009 | CN100453556C Multispecific deimmunized CD3-binders |
| 01/20/2009 | US7479554 AAV5 nucleic acids |
| 01/20/2009 | US7479546 Pro104 antibody compositions and methods of use |
| 01/20/2009 | US7479545 Used as pharmaceuticals, diagnostics, biosensors and bioreactors |
| 01/20/2009 | US7479544 biological conjugated drug binding with a detectable label, or toxin maytansine and calicheamicin; monoclonal antibody as antiinflammatory agents in the therapeutic treatment and diagnostic detection of immune disorders in mammals; biodrugs |
| 01/20/2009 | US7479543 chimeric antibodies comprising variable domain peptides, DNA codes for the antibodies, expression vectors, host cells and a process of culturing the host cells to produce the monoclonal antibodies, used for immunotherapy; nonimmunogenic |
| 01/20/2009 | US7479541 and fusion proteins with green fluorescent protein, used for modulating cell differentiation and apoptosis, including cell formation of tissues |
| 01/20/2009 | US7479539 Hedgehog fusion proteins |
| 01/20/2009 | US7479537 Reagents and methods useful for detecting diseases of the breast |
| 01/20/2009 | US7479481 Treatment of ocular diseases and disorders using lantibiotic compositions |
| 01/20/2009 | US7479386 Hepatitis X virus for use in generation of antibody and vaccine compositions for use in diagnosis, prevention and treatment viral infection; immunotherapeutic and diagnostics |
| 01/20/2009 | US7479379 Methods for altering protein production rates |
| 01/20/2009 | US7479372 Beta-secretase substrates and uses thereof |
| 01/20/2009 | US7479371 quantifying stem cell growth factor (SCGF); two different anti-SCGF antibodies are used in the sandwich assay, wherein the two different anti-SCGF antibodies react with different epitopes of stem cell growth factor; acute lymphocytic leukemia; acute myeloid leukemia; chronic myeloid leukemia |
| 01/20/2009 | US7479280 Papilloma virus capsid support comprising chimeric lymphocyte epitope for use in identifying modulators to treat and prevention cell proiferative, autoimmune and viral diseases |
| 01/20/2009 | US7479279 Use of cytokines of the TGF-β superfamily for the treatment, inhibition and/or diagnosis of skin related disorders |
| 01/20/2009 | US7479271 Appetite hormone specific immunoglobulin for prevention and treatment of eating and weight related disorders |
| 01/20/2009 | US7479270 Methods and compositions for activating VEGF-D and VEGF-C |
| 01/20/2009 | CA2258512C Amidases, nucleic acids encoding them and methods for making and using them |
| 01/20/2009 | CA2137822C Method for detecting pre-cancerous or cancerous cells using p90 antibodies or probes |
| 01/20/2009 | CA2108473C Heregulins (hrgs) binding proteins of p185erb2 |
| 01/15/2009 | WO2009009706A1 Method for removing endotoxin from proteins |
| 01/15/2009 | WO2009009103A2 CRYSTALS AND STRUCTURE OF HUMAN IgG Fc VARIANT |
| 01/15/2009 | WO2009008916A2 Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| 01/15/2009 | WO2009008529A1 Antibody binding specifically to tdp-43 aggregate |
| 01/15/2009 | WO2009008496A1 Anti-hsulf1 antibody |
| 01/15/2009 | WO2009008414A1 Monoclonal antibody having neutralizing activity against mmp13 |
| 01/15/2009 | WO2009007993A2 A process for purification of immunoglobulins using a pseudobioaffinity adsorbent |
| 01/15/2009 | WO2009007427A2 Novel antibodies inhibiting c-met dimerization, and uses thereof |
| 01/15/2009 | WO2009007272A1 Novel formulation |
| 01/15/2009 | WO2009007222A1 An antibody specific for the tn antigen for the treatment of cancer |
| 01/15/2009 | WO2009007124A1 Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| 01/15/2009 | WO2008140415A9 H5 subtype-specific binding proteins useful for h5 avian influenza diagnosis and surveillance |
| 01/15/2009 | WO2008113013A3 C-met mutations and uses thereof |
| 01/15/2009 | WO2008110885A3 Methods of treating ophthalmic diseases |
| 01/15/2009 | WO2008088582A9 Methods and materials related to trail isoforms |
| 01/15/2009 | WO2008085951A3 Treatment of tumors by ablating bone marrow-derived endothelial progenitor cells |